JPMorgan Chase & Co. Issues Positive Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its target price boosted by JPMorgan Chase & Co. from $110.00 to $120.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare product maker’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 18.87% from the company’s current price.

A number of other research firms have also issued reports on ABT. Argus reduced their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. The Goldman Sachs Group cut their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a report on Wednesday, April 22nd. Evercore dropped their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, UBS Group cut their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.30.

Abbott Laboratories Stock Performance

ABT traded up $2.12 on Friday, hitting $100.95. 7,051,367 shares of the company’s stock were exchanged, compared to its average volume of 12,309,600. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a fifty day moving average of $89.56 and a two-hundred day moving average of $102.18. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The firm has a market cap of $175.83 billion, a PE ratio of 28.28, a P/E/G ratio of 1.54 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors have recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported better-than-expected Q2 adjusted EPS of $1.31 and raised full-year 2026 EPS guidance to $5.45-$5.60, signaling improved profitability and management confidence. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management said the second half should be stronger, with growth drivers spanning nutrition, medical devices, diagnostics and diabetes care, helping reinforce the case for sustained momentum. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Several analysts turned more constructive after the earnings beat, including Wells Fargo raising its price target to $112, TD Cowen reaffirming a Buy with a $115 target, RBC reiterating Outperform with a $130 target, and BTIG lifting its target to $134. Benzinga analyst rating updates
• Neutral Sentiment: Revenue came in roughly in line with expectations at $12.51 billion, while the company also highlighted strong demand in medical devices and diagnostics, but some articles noted continued weakness in nutrition and a lower reported profit versus last year. Abbott raises 2026 profit forecast on heart device strength

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.